Lead Product(s) : Tislelizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
Details :
Product Name : Tevimbra
Product Type : Antibody
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Tislelizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bevacizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Etana
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Bevagen
Product Type : Antibody
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Bevacizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Etana
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nivolumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approvals are based on the Phase 3 trial, which evaluated Opdivo (Nivolumab) in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase 3 trial of an immunotherapy in...
Product Name : Opdivo
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Nivolumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The CHMP’s recommendation was based on results from Phase 2 KEYNOTE-158 trial as well as results from Phase 2 KEYNOTE-164 trial, both of which supported U.S.FDA accelerated approval of KEYTRUDA as cancer treatment approved based on a biomarker in MSI-H...
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
March 25, 2022
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Provides Update on KEYTRUDA® (Pembrolizumab) Indication in Third-Line Gastric Cancer in the US
Details : KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable